机译:可溶性白细胞介素-2受体和C反应性蛋白质与惰性淋巴瘤和外壳细胞淋巴瘤的效果
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Division of Hematology Department of Medicine Showa University Fujigaoka Hospital Yokohama Japan;
Division of Hematology Department of Medicine Showa University School of Medicine Tokyo;
Bendamustine; C-reactive protein; Mantle cell lymphoma; Non-Hodgkin lymphoma;
机译:可溶性白细胞介素-2受体和C反应性蛋白质与惰性淋巴瘤和外壳细胞淋巴瘤的效果
机译:具有Bendamustine Plus Rituximab的惰性非霍奇金淋巴瘤或披风细胞淋巴瘤患者的一线治疗与R-Chec或R-CVP:明亮5年后续研究的结果
机译:Bendamustine作为晚期惰性非霍奇金淋巴瘤和套细胞淋巴瘤的一线治疗方法,在德国的常规临床实践中
机译:地幔细胞淋巴瘤和肾移植
机译:惰性B细胞淋巴瘤的DNA损伤,细胞周期停滞和凋亡机制。
机译:苯达莫司汀作为晚期惰性非霍奇金淋巴瘤和套细胞淋巴瘤的一线治疗在德国的常规临床实践中
机译:基因多态性作为惰性非霍奇金淋巴瘤患者治疗疗效和毒性的预测因子,接受Bendamustine和Rituximab的患者